The funds will go towards scaling C2N Diagnostics’ laboratory services and advancing the company’s range of diagnostic tests.

it has contributed to the stabilization of the biopharmaceutical supply chain and better access to high quality bio pharmaceutics,” Jaywoo Kim, executive VP of Samsung C&T, said in a statement.

Jaywoo Kim, Executive Vice President of Samsung C&T Corporation, says, "Since Samsung C&T stepped into the life sciences industry by investing in biologics CDMO and biosimilar business ...

C2N says Samsung’s decision bolsters its ability to further scale its clinical laboratory services and advanced diagnostic solutions in the field of brain health. Jaywoo Kim, Executive Vice President ...

This agreement accomplishes both objectives." Jaywoo Kim, head of the commercial division at Samsung Bioepis, said: “The earliest impact of this agreement will likely be seen in Europe ...